Edgar Filing: ALDER BIOPHARMACEUTICALS INC - Form 4

ALDER BIC Form 4 June 08, 201	OPHARMACE	EUTICALS	INC								
FORM									OMB A	PPROVAL	
	UNITE	CD STATE		ITIES Al hington,			NGE (COMMISSION	OMB Number:	3235-0287	
Check th	aar			_					Expires:	January 31,	
Section 16. Form 4 or Form 5 Filed pursuant to S				S CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Section 16(a) of the Securities Exchange Act of 1934,						Expires. 200 Estimated average burden hours per response 0.	
obligatio may cont <i>See</i> Instru 1(b).	tinue. Section		Public Ut	•	•	- ·		f 1935 or Sectio 40	n		
(Print or Type I	Responses)										
1. Name and A JAGGERS	Address of Report JOHN V	ing Person <u>*</u>	Symbol	Name and BIOPHA .DR]				5. Relationship of Issuer (Chec	Reporting Per		
(Last)	(First)	(Middle)	-	- Earliest Tra	insaction			Director	X 104	% Owner	
	I ROSEN FUN AD, SUITE 13:		(Month/Da 06/04/20	-				Officer (give below)	titleOth below)	er (specify	
DALLAS, 7	(Street)			ndment, Dat th/Day/Year)	-			6. Individual or Jo Applicable Line) Form filed by D _X_ Form filed by I	One Reporting Pe	erson	
								Person			
(City)	(State)	(Zip)	Table	e I - Non-Do	erivative S	Securi	ties Aco	quired, Disposed of	f, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr. 8)	(Instr. 3, 4 and 5) (A) or		Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)					
Common				Code V		(D)	Price		_		
Stock	06/04/2015			J <u>(1)</u>	4,547	А	\$0	4,547 <u>(2)</u>	D		
Common Stock	06/04/2015			J <u>(1)</u>	1,392	А	\$0	1,392 <u>(3)</u>	D		
Common Stock	06/04/2015			J <u>(1)</u>	3,664	А	\$0	3,664 <u>(4)</u>	D		
Common Stock	06/04/2015			J <u>(1)</u>	3,664	А	\$0	3,664 <u>(5)</u>	D		
Common Stock	06/04/2015			J <u>(1)</u>	2,782	А	\$0	2,782 (6)	D		

Edgar Filing: ALDER BIOPHARMACEUTICALS INC - Form 4

Common Stock	06/04/2015	J <u>(1)</u>	2,340	А	\$0	2,340 (7)	D	
Common Stock	06/04/2015	J <u>(1)</u>	4,547	А	\$0	4,547 <u>(8)</u>	D	
Common Stock	06/04/2015	J <u>(1)</u>	2,340	А	\$0	2,340 <u>(9)</u>	D	
Common Stock						2,024,483 (10)	Ι	See Footnote (10)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Derivative Security	2. Conversion or Exercise	3. Transaction Date (Month/Day/Year)	Execution Date, if any	4. Transactio Code	of	6. Date Exerce Expiration D (Month/Day/	ate	7. Title Amour Underl	nt of ying	8. Price of Derivative Security	9. Nu Deriv Secu
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivative			Securit		(Instr. 5)	Bene
	Derivative				Securities			(Instr.	3 and 4)		Owne
	Security				Acquired						Follo
					(A) or						Repo
					Disposed						Trans
					of (D)						(Instr
					(Instr. 3,						
					4, and 5)						
					,						
									Amount		
						Date	Expiration		or		
						•	•	Title	Number		
						Exercisable	Date		of		
				Code V	(A) (D)				Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
JAGGERS JOHN V C/O SEVIN ROSEN FUNDS 13355 NOEL ROAD, SUITE 1350 DALLAS, TX 75240		Х			
BAYLESS JON W C/O SEVIN ROSEN FUNDS 13455 NOEL ROAD, SUITE 1670 DALLAS, TX 75240		Х			

06/05/2015 Date 06/05/2015 Date

06/05/2015

Date

06/05/2015

Date

06/05/2015

Date

DOMENIK STEPHEN L C/O SEVIN ROSEN FUNDS 13455 NOEL ROAD, SUITE 1670 DALLAS, TX 75240	Х
KIMZEY JACKIE R SEVIN ROSEN FUNDS 13355 NOEL ROAD, SUITE 1350 DALLAS, TX 75240	X
McLean David J. C/O SEVIN ROSEN FUNDS 13455 NOEL ROAD, SUITE 1670 DALLAS, TX 75240	X
OXAAL JOHN T C/O SEVIN ROSEN FUNDS 13455 NOEL ROAD, SUITE 1670 DALLAS, TX 75240	X
SCHUELE ALAN R C/O SEVIN ROSEN FUNDS 13455 NOEL ROAD, SUITE 1670 DALLAS, TX 75240	X
STURIALE NICHOLAS G C/O SEVIN ROSEN FUNDS 13455 NOEL ROAD, SUITE 1670 DALLAS, TX 75240	X
Signatures	
John V. Jaggers	
<u>**</u> Signature of Reporting Person	
John V. Jaggers, As Attorney-In-Fact For Jon W.	Bayless
<u>**</u> Signature of Reporting Person	
John V. Jaggers, As Attorney-In-Fact For Stephen Domenik	L.
<u>**</u> Signature of Reporting Person	

John V. Jaggers, As Attorney-In-Fact For Jackie R. Kimzey <u>**Signature of Reporting Person</u> John V. Jaggers, As Attorney-In-Fact For David J. McLean

**Signature of Reporting Person

John V. Jaggers, As Attorney-In-Fact For John T. Oxaal	06/05/2015
**Signature of Reporting Person	Date
John V. Jaggers, As Attorney-In-Fact For Alan R. Schuele	06/05/2015

Edgar Filing: ALDER BIOPHARMACEUTICALS INC - Form 4

**Signature of Reporting Person

Date

John V. Jaggers, As Attorney-In-Fact For Nicholas G. Sturiale

**Signature of Reporting Person

06/05/2015 Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents a pro rata in-kind distribution, without additional consideration, of 1,973,885 shares of Common Stock of the Issuer by Sevin Rosen Fund IX L.P. and 50,552 shares of Common Stock of the Issuer by Sevin Rosen IX Affiliates Fund L.P.
- (2) Represents the receipt of shares by John V. Jaggers ("Jaggers") of Common Stock of the Issuer by virtue of the pro rata in-kind distribution described in footnote (1) above.
- (3) Represents the receipt of shares by Jon W. Bayless("Bayless") of Common Stock of the Issuer by virtue of the pro rata in-kind distribution described in footnote (1) above.
- (4) Represents the receipt of shares by Stephen L. Domenik ("Domenik") of Common Stock of the Issuer by virtue of the pro rata in-kind distribution described in footnote (1) above.
- (5) Represents the receipt of shares by Jackie R. Kimzey ("Kimzey") of Common Stock of the Issuer by virtue of the pro rata in-kind distribution described in footnote (1) above.
- (6) Represents the receipt of shares by David J. McLean ("McLean") of Common Stock of the Issuer by virtue of the pro rata in-kind distribution described in footnote (1) above.
- (7) Represents the receipt of shares by John T. Oxaal ("Oxaal") of Common Stock of the Issuer by virtue of the pro rata in-kind distribution described in footnote (1) above.
- (8) Represents the receipt of shares by Alan R. Schuele ("Schuele") of Common Stock of the Issuer by virtue of the pro rata in-kind distribution described in footnote (1) above.
- (9) Represents the receipt of shares by Nicholas G. Sturiale ("Sturiale") of Common Stock of the Issuer by virtue of the pro rata in-kind distribution described in footnote (1) above.

Total Common Shares of 2,024,483 represents 46 shares owned directly by SRB Associates IX L.P. ("SRBAIX"), 1,973,885 shares owned directly by Sevin Rosen Fund IX L.P. ("SRFIX") and 50,552 shares owned directly by Sevin Rosen IX Affiliates Fund L.P. ("SRIX AFF"). SRBAIX is the general partner of SRFIX and SRIX AFF, and in that capacity has shared voting and dispositive power

(10) over such shares. SRBAIX disclaims beneficial ownership of such shares except to the extent of its pecuniary interest. Jaggers, Bayless, Domenik, Kimzey, McLean, Oxaal, Schuele and Sturiale are members of the general partner of SRBAIX, and as members are deemed to have shared voting and dispositive power of the shares and disclaim beneficial ownership of these shares except to the extent of his proportionate interest in these shares.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.